ReviewCancers2021
Immunotherapy Predictive Molecular Markers in Advanced Gastroesophageal Cancer: MSI and Beyond.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- Development and validation of a collagen score-based prediction model for neoadjuvant chemoimmunotherapy efficacy in locally advanced esophageal squamous cell carcinoma.Journal of thoracic disease · 2026Article
- Peripheral blood cells predict the efficacy and prognosis of neoadjuvant immunotherapy combined with chemotherapy for esophageal squamous cell carcinoma.BMC cancer · 2025Article
- Organ preservation in esophageal cancer treatment, is it time now?World journal of gastroenterology · 2025Review
- Prognostic molecular subtype reveals the heterogeneity of tumor immune microenvironment in gastric cancer.Scientific reports · 2025Article
- Biomarkers for colorectal cancer detection: An insight into colorectal cancer and FDA-approved biomarkers.BioImpacts : BI · 2025Review
- Who Should Receive Immunotherapy for Advanced Gastroesophageal Cancer?Current treatment options in oncology · 2024Review
- Development and validation of a novel lysosome-related LncRNA signature for predicting prognosis and the immune landscape features in colon cancer.Scientific reports · 2024Article
- From tumor microenvironment to emerging biomarkers: the reshaping of the esophageal squamous cell carcinoma tumor microenvironment by neoadjuvant chemotherapy combined with immunotherapy.Frontiers in immunology · 2024Review
- Article
- POLD4 Promotes Glioma Cell Proliferation and Suppressive Immune Microenvironment: A Pan-Cancer Analysis Integrated with Experimental Validation.International journal of molecular sciences · 2023Article
- Review
- Review
- Elevated THBS3 predicts poor overall survival for clear cell renal cell carcinoma and identifies LncRNA/RBP/THBS3 mRNA networks.Cell cycle (Georgetown, Tex.) · 2023Article
- A telomerase regulation-related lncRNA signature predicts prognosis and immunotherapy response for gastric cancer.Journal of cancer research and clinical oncology · 2023Article
- Molecular Biomarkers in Cancer.Biomolecules · 2022Review
- Long-term benefit of immunotherapy in a patient with squamous lung cancer exhibiting mismatch repair deficient/high microsatellite instability/high tumor mutational burden: A case report and literature review.Frontiers in immunology · 2022Review
- Oxidative stress-related patterns determination for establishment of prognostic models, and characteristics of tumor microenvironment infiltration.Frontiers in surgery · 2022Article
- Pancancer Analysis of RevealedDisease markers · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advanced gastroesophageal cancer (GEC) has a poor prognosis and limited treatment options. Immunotherapy including the anti-programmed death-1 (PD-1) antibodies pembrolizumab and nivolumab have been approved for use in various treatment settings in GEC. Additionally, frontline chemoimmunotherapy regimens have recently demonstrated promising efficacy in large phase III trials and have the potential to be added to the therapeutic armamentarium in the near future. There are currently several immunotherapy biomarkers that are validated for use in the clinical setting for GEC including programmed death ligand-1 (PD-L1) expression as well as the tumor agnostic biomarkers such as mismatch repair or microsatellite instability (MMR/MSI) and tumor mutational burden (TMB). However, apart from MMR/MSI, these biomarkers are imperfect because none are highly sensitive nor specific. Therefore, there is an unmet need for immunotherapy biomarker development. To this end, several biomarkers are currently being evaluated in ongoing trials with some showing promising predictive potential. Here, we summarize the landscape of immunotherapy predictive biomarkers that are currently being evaluated in GEC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.